title: Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.
abstract: Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.
authors.affiliation: Mayo Clinic, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA. temesgen.zelalem@mayo.edu
authors.forename: Zelalem
authors.initials: Z
authors.lastname: Temesgen
authors.forename: Judith E
authors.initials: JE
authors.lastname: Feinberg
mesh_terms: D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D004353:Drug Evaluation, Preclinical; D015683:Gene Products, gag / Q000037:antagonists & inhibitors*; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D015497:HIV-1 / Q000378:metabolism*; D006801:Humans; D013386:Succinates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D014315:Triterpenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D053978:Pentacyclic Triterpenes
chemical_list: D015683:Gene Products, gag; D013386:Succinates; D014315:Triterpenes; C479935:bevirimat; D053978:Pentacyclic Triterpenes